The objectives were two-fold:
Methods of synthesis
How were the studies combined? The studies were combined in a meta-analysis using the random-effects model of DerSimonian and Laird (see Other Publications of Related Interest).
How were differences between studies investigated?
Heterogeneity was assessed using the method described by DerSimonian and Laird (see Other Publications of Related Interest). Large variations in the inclusion criteria led to relapse being examined according to prognostic factors within the individual studies.
Results of the review
Twenty-five studies (5,354 participants) were included.
Risk of relapse.
The RR was 0.25 (95% CI: 0.21, 0.30) at one year and 0.29 (95% CI: 0.24, 0.34) at 2 years. Substantial heterogeneity was present among the relapse risks from these studies (p<0.0001).
Age of onset of epilepsy.
For childhood versus adolescence, the RR was 1.79 (95% CI: 1.46, 2.19); there was significant heterogeneity (p=0.002).
For childhood versus adult, the RR was 1.34 (95% CI: 1.00, 1.81); heterogeneity was not quite significant (p=0.063).
Underlying etiology.
For idiopathic seizures versus remote symptomatic, the RR was 1.55 (95% CI: 1.21, 1.98); there was significant heterogeneity (p<0.0001).
For idiopathic seizures associated with mental retardation, the RR was 1.66 (95% CI: 1.30, 2.12); heterogeneity was not significant (p=0.98).
For idiopathic seizures associated with motor deficits, the RR was 1.79 (95% CI: 1.13, 2.83); there was significant heterogeneity (p<0.0001).
Electroencephalogram.
For an abnormal electroencephalogram associated with risk of relapse, the RR was 1.45 (95% CI: 1.18, 1.79); there was significant heterogeneity (p<0.0002).
Authors' conclusions
In relatively unselected groups of seizure-free patients, the risk of relapse after discontinuing AEDs was 25% at one year and 29% at two years. Onset during adolescence appeared to carry the highest risk of relapse, while onset during childhood had the lowest risk.
Not surprisingly, remote symptomatic seizures were associated with an increased risk of relapse.
In most studies there was a relationship between an abnormal electrocencephalogram and an increased risk of relapse.
These meta-analyses were an attempt to provide a framework to be used in making rational decisions that best meet the specific needs of individual patients. However, they should not be used as the sole basis for decisions on whether to discontinue medication.
CRD commentary
This systematic review satisfied several of the criteria for inclusion in the DARE database. The authors' conclusions appear valid from the data presented in the review, although the results may not be directly generalisable to clinical practice.
The design of the included studies was an important factor in determining the strength of the conclusions. Unfortunately, the study designs were not well described and a variety of study designs may have been included; this partially explains the heterogeneity between the studies. The presence of heterogeneity indicates that it would have been advantageous had other aspects that influence the strength of the evidence been reported; perhaps consideration should have been given to the use of a formal validity assessment.
The search strategy was essentially restricted to Index Medicus, and the dates over which the search was conducted were not given. Despite including studies published in several languages, it is possible that the search missed several studies not represented in this single database.
